Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the nan trial

HIGHLIGHTS

• who: Dou-Dou Li from the vinorelbine combined with apatinib can refer to a phase I/II study of vinorelbine combined with sorafenib Besides, the side effects of apatinib need time to recover in order to increase drug tolerance, so compare with navelbine monotherapy arm, we conducted the dose reduction of navelbine. Multiple targeted therapies have achieved drastic improvements in the treatment of metastatic TNBC. Recently clinical studies showed that adding programmed death receptor , (PD-1) or its ligand (PD-L1) blockade to chemotherapy significantly improved PFS in PD-, positive mTNBC patients51-53. PARP inhibitors, Olaparib and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.